CannTrust (CNSX:TRST) had its price objective hoisted by equities researchers at Canaccord Genuity from $7.25 to $9.50 in a note issued to investors on Monday, December 4th.
CannTrust (CNSX TRST) traded up C$0.34 during midday trading on Monday, reaching C$8.74. 77,285 shares of the company’s stock traded hands, compared to its average volume of 24,035. CannTrust has a fifty-two week low of C$1.69 and a fifty-two week high of C$8.74.
In other news, Director Mark Litwin sold 244,750 shares of CannTrust stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of C$7.35, for a total transaction of C$1,798,912.50. Also, Director Mitchell J. Sanders sold 20,000 shares of CannTrust stock in a transaction dated Friday, November 24th. The shares were sold at an average price of C$7.70, for a total transaction of C$154,000.00.
ILLEGAL ACTIVITY NOTICE: “Canaccord Genuity Boosts CannTrust (CNSX:TRST) Price Target to $9.50” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/14/canntrust-trst-price-target-increased-to-9-50-by-analysts-at-canaccord-genuity.html.
CannTrust Company Profile
CannTrust Holdings Inc is a Canada-based company, which produces pharmaceutical-grade medical cannabis for patients. The Company is a federally regulated licensed producer of medical cannabis products. The Company operates a hydroponic facility and an onsite laboratory for testing and research on the medical use of cannabis.
Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.